TrialLancet (London, England)2020

Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial.

Richard O Phillips et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.